Most Read

On March 2nd, 2019, TaiwanJ announced that its JKB-122, an effective phase 2 nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) drug candidate, had been successfully licensed out to

Proceeds from the financing will be used to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific

The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such

Promacta (eltrombopag) is known as Revolade outside the US and is marketed worldwide by Novartis. This transaction is expected to close on Wednesday, March 6, 2019. “After extensive

Fedratinib is a highly selective JAK2 inhibitor intended for the treatment of patients with myelofibrosis, a serious bone marrow disorder that disrupts the body’s normal production of blood

The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9%

The collaboration leverages Abpro’s proprietary DiversImmuneTM antibody discovery platform. Under  the  terms  of  the  agreement,  Abpro  is  eligible to  receive up  to  $4  billion,  including $60 million  in 

Financial terms of the transaction have not been disclosed. The manufacturing site, which is approved for manufacturing of both small molecule and biologic products, is the first FDA-approved

This new treatment includes the same monoclonal antibody as intravenous Herceptin® (trastuzumab) in combination with recombinant human hyaluronidase PH20, an enzyme that helps to deliver trastuzumab under the